Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Sep 2019: Trial registered, NCT04105270
  2. 30 Nov 2022: Trial started, NCT04105270

The trials

NCT04105270: RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

State
Under way
Phase
Phase 2
People
82 planned
Started
30 Nov 2022
Primary completion
Jan 2028
Arms
Arm B (Placebo)
Results
None posted
  1. 26 Sep 2019: Trial registered
  2. 30 Nov 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.